Refine your search
Collections
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Jadhav, Anil G.
- Hepatoprotective Activity of Bauhinia variegata Bark against Carbon Tetrachloride Induced Hepatotoxicity in Female Albino Wistar Rats
Abstract Views :227 |
PDF Views:4
Authors
Affiliations
1 Dept. of Pharmacognosy KLES College of Pharmacy, Belgaum, Karnataka, IN
2 Dept. of Pharmacognosy Smt.BNB Swaminarayan Pharmacy College, Salvav (Vapi), IN
3 Veerayatan Institute of Pharmacy, Jakhania, Bhuj-Mandvi Road, Kutch-370460, Gujarat, IN
1 Dept. of Pharmacognosy KLES College of Pharmacy, Belgaum, Karnataka, IN
2 Dept. of Pharmacognosy Smt.BNB Swaminarayan Pharmacy College, Salvav (Vapi), IN
3 Veerayatan Institute of Pharmacy, Jakhania, Bhuj-Mandvi Road, Kutch-370460, Gujarat, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 2, No 3 (2010), Pagination: 239-242Abstract
In recent times lot of interest has been generated to find out a natural remedy for hepatic disorders caused by toxins like alcohol and hepatitis virus. The present study is designed and investigate the hepatoprotective activity of Bauhinia variegata bark against carbon tetrachloride (CCl4) induced hepatotoxicity in female Albino Wistar rats. Forty two Albino Wistar female rats were divided in to seven equal groups each containing six animals. Four groups received the extracts of Bauhinia variegata bark and intraperitoneal (i.p.) CCl4 (2 ml/kg) with administration of extracts. One group was control, one treated with CCl4 and one with normal saline. The hepatotoxicity was assessing by plasma concentration of serum bilirubin and enzymes activities. The aqueous extract (500mg/kg b.w.) of Bauhinia variegata bark significantly reduced carbon tetrachloride induce damages in the liver which is measured by SGOT, SGPT, SALP and serum bilirubin levels in blood. The attempt has been made to extract the active constituent and identified by phytochemical investigation and hepatoprotective activity of Bauhinia variegata bark.Keywords
Bauhinia variegata
References
- Ambasta SP. The Useful Plants of India. Publication and Information Directorate, New Delhi; 1992, pp. 69-70.
- Arya Vaidya Sala. Indian Medicinal Plants - A Compendium of 500 Species. Orient Longman Ltd., Madras; Vol.I., 1998 pp. 256-257.
- Handa SS. Sharma A, Hepatoprotective activity of andrographolide from Andrographis paniculata against CCL4. Indian J Med Res, 92(8):137-140 (1990).
- Hussain Z, Waheed A and Qureshi RA .The effect of medicinal plants of Islamabad and Murree region of Pakistan on insulin secretion from INS-1 cells. Phytother Res; 18(1): 73-77 (2004).
- Kapoor LD. Handbook of Ayurvedic medicinal plants. Dubli CRC Press LLC, New York; 2000, pp.71.
- Kind PR and King EJ. Estimation of plasma phosphatase by determination of hydrolyzed phenol with antipyrine. J. Clin. Pathol;7: 322 (1954)
- Kirtikar KR and Basu BD. Indian Medicinal Plants;, Vol.I,1996, pp. 898-900.
- Nadkarni AK. The Indian Materia Medica. Popular Prakashan, Bombay; Vol.I Reprint 1999, 184-185.
- Ojha, J.K. Dwivedi, K.N. Effect of plant exracts on non healing diabetic foot ulcers, Sachitra Ayurved; V 48(9): 870-874 (1996).
- Pokhrel, Naba Raj, R.P. Adhikari and M.P. Baral. In-vitro evaluation of the antimicrobial activity of Bauhinia variegata. World Journal of Microbiology and Biotechnology; 18(1): 69-71(2002).
- Rajkapoor B, Jayakar B, Murugesh N. Antitumour activity of Bauhinia variegata on Dalton's ascitic lymphoma. J Ethnopharmaco.; Nov; 89(1): 107-109 (2003).
- Rajkapoor, B., B. Jayakar, R. Anandan and S. Kavimani. Antiulcer effect of Bauhinia variegata Linn. in rats, Journal of Natural Remedies; 3: 2-4 (2003).
- Rajkapoor, BB, Jayakar and Murugesh N. Antitumour activity of Bauhinia variegata against Ehrlich ascites carcinoma induced mice, Pharmaceutical Biology; 41, 8: 604-607 (2003).
- Reitman, S. and Frankel AS. A colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol.; 26: 56-57 (1967).
- Shivrajan VV, and Indira B. Ayurvedic drugs and their plants sources, Oxford and IBH publishers, New Delhi; 2004, pp.207.
- The Wealth of India - A Dictionary of Indian Raw Materials and Industrial products. Vol-I, CSIR, New Delhi, 1952. Reprint 1989, pp. 161.
- Vaidya VM, Gogte. Ayurvedic Pharmacology and Therapeutic uses of medicinal plant. Published by Shri S. Ramkrishanan Executive Secretary, Bhartia Vaidya Bhavan, Kulapati manshi marg, Mumbai; Reprint 2000, pp. 340.
- Yadava RN, Reddy VM. Anti-inflammatory activity of a novel flavonol glycoside from the Bauhinia variegata Linn ; Nat Prod Res.17(3):165-9 (2003).
- New Approaches to Antiretroviral Therapy - Raltigravir
Abstract Views :206 |
PDF Views:0
Authors
Affiliations
1 Smt. B. N. B. Swaminarayan Pharmacy College, Salvav, Vapi, IN
1 Smt. B. N. B. Swaminarayan Pharmacy College, Salvav, Vapi, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 3, No 2 (2011), Pagination: 58-66Abstract
AIDS is a disease caused by the retrovirus Human Immunodeficiency Virus (HIV) and is characterized by the profound immunosuppression that leads to the opportunistic infection, secondary neoplasm and neurologic manifestation. The magnitude of this modern plague is truly staggering. By the end of the 2008, more than 190000 causes of ADIS have been reported in the USA, AIDS is a global problem worldwide. AIDS has now been reported from more 193 countries.
Here we introduce recent therapies used in the treatment of AIDS, like highly active antiretroviral therapy. Also here we introduce drugs clinical trial like BT378/r and HIV vaccine. Our main focus is to high light an integrase inhibitor-Raltegravir which is a new category of drug.
By reviewing Raltegravir's mechanism, pharmacological parameter we conclude that an integrase inhibitor which is active against retrovirus, found to be more beneficial compare to other currently use drugs, and also be found to be effective against resistive subject and increase their like livelihood.
Keywords
Integrase Inhibitor, Raltegravir.References
- Harsh M. Textbook Of Pathology. 2006;4:52 -53.
- Thomas J., Gordan A. Pathophysilogy Concepts and Applications Of Health care Professionals 2004;5:115-116.
- Padmaja U. Textbook Of Medical Pharmacology. 2009;2:407-410.
- Katzung. Basic and Clinical Pharmacology. 2007;10:799-801.
- Alfred G.G. The Pharmacological Basis Of Therapeutics. 2006;10:1341-1351.
- Landman R. et al. Evaluation at 6 months of a Once-a-Day HAART Regimen in Treatment-Naive HIV-1-Infected Adults in Senegal (ANRS 12-04 Study). Abstract 491, 8th Conference on Retroviruses and Opportunistic Infections.
- Diop Y. et al. Prospective Trials of CBV + IDV in West Africa [Cote-d'Ivoire], Abstract 492, 8th Conference on Retroviruses and Opportunistic Infections.
- Rang H.P. et al. Pharmacology. Churchill Livingstone.2003;5:659-665.
- www.nari_icmr.resin/antiretroviral_fag.html.National AIDS Research Institute, Pune, India.(viewed on 01 May 2006)
- Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H. , Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect. 2005;191:654-665.
- Pitisuttithum P., Gilbert P., Gurwith M. et al. Randomized double-blind placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect. 2006;194:1661-1671.
- http:// www.link.med.ed.ac.uk, HIV and aids introduction. (viewed on 22 December 2009)
- http://www.rxlist.com , Rxlist, Raltegravir. The internet drug index. (viewed on 10 Nov 2008)
- Grinstein., Beatriz., et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment experienced patients with multi-drug resistant virus: a phase II randomized controlled trial. The Lancet. 2007;369:1261-1269.
- AIDSMEDS.com 7 August 2007. http://www.aidsmeds.com/archive/MK-0518_1639.shtml (viewed on 22 December 2009)
- Markowitz M., Nguyen B.Y., Gotuzzo E. et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. 2007;46(2):125–133.
- Stephenson J. Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus. JAMA. 2007;14:1535.
- Faster Viral Decay with Raltegravir - The Body http://www.the body.com/content/art42654.html. (viewed on 24 December 2009)
- Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients with Previous Complete Viral Suppression. ClinicalTrials.gov Available at http://clinicaltrials.gov/ct2/showNCT00554398. (viewed on 24 December 2009)
- www.hivanhepatitis.com, Raltegravir (isentress) (viewed on 24 December 2009).
- Natap.org - Conference Reports: 10th European AIDS Conference. MK-0518, the First Integrase Inhibitor for HIV, No Blarney. Available at: http://www.natap.org/2005/EACS/eacs_3.htm. Accessed 06/30/08. (viewed on 25 December 2009).
- HIV and Hepatitis.com - Merck Announces Interim Results from Phase II Study of MK-0518, an Investigational Oral HIV Integrase Inhibitor. Available at:http://www.hivandhepatitis.com/2006icr/croi/docs/021006_b.html. (viewed on 22 December 2009).
- Scott A; Daniel; rouzioux; Acquired Immune Deficiency Syndrome. JAIDS. 2007;46(2):125-133.
- Merck and Company – Isentress prescribing Information, May 2008, p. 3. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08. (viewed on 25 December 2009).
- Merck and Company - FDA Approves Isentress (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor [Press Release], October 12,2007. Available at: http://www.merck.com/newsroom/press_releases/product/2007_1012.html. Accessed 06/30/08 (viewed on 27 December 2009).
- Merck and Company - Isentress Prescribing Information, May 2008, p. 4. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08 (viewed on 27 December 2009).
- Merck and Company - Isentress Prescribing Information, May 2008, p. 2. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08. (viewed on 27 December 2009).
- Intersci Conf Antimicrob Agents Chemother - 46th,(2006). Abstract H-1383.
- Merck and Company - Isentress Prescribing Information, May 2008, p. 1-2. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08(viewed on 27 December 2009).
- De clerk., Vandamme E., A-M combination Therapy of AIDS. Birkhauser verlag; Germany in 2004.
- Merck and Company - Isentress Prescribing Information ( May 2008), p. 1. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08 (viewed on 27 December 2009).
- Merck and Company - Isentress Prescribing Information ( May 2008), p. 13. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08. (viewed on 27 December 2009).
- Merck and Company - Isentress Prescribing Information ( May 2008), p. 7. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08. (viewed on 27 December 2009).
- Cooper D., Gatell J., Rockstroh J. et al. Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus. Oral abstract 105LBa. http://www.retroconference.org/2007/Abstracts/30687.html (viewed on 2 January 2010).
- Steigbigel R., Kumar P., Eron J. et al. Results of BENCHMRK-2, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus. Oral abstract 105LB. http://www.retroconference.org/2007/Abstracts/30688.html (viewed on 2 January 2010).
- http://www.futuremedicine.com, Future HIV therapy. 2008 (May); 2(3);217-227(viewed on 2 January 2010).